Functional Dyspepsia (Investigational Adjunct)
Investigational adjunct for functional dyspepsia (Rome IV criteria); H. pylori eradication when positive, proton pump inhibitors, prokinetics, and tricyclic antidepressants remain evidence-based.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for functional dyspepsia. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for functional dyspepsia is investigational.
- What evidence exists?
- Tier C (investigational). No clinical study of leech therapy for functional dyspepsia was identified in PubMed or Europe PMC. Evidence-based therapy for functional dyspepsia per ACG guidelines: test-and-treat for Helicobacter pylori (urea breath test or stool antigen, eradicate if positive), proton pump inhibitor trial, low-dose tricyclic antidepressant (amitriptyline 10-25 mg) for epigastric pain (ulcer-like) dyspepsia, prokinetics (metoclopramide short-course, itopride), and psychological therapies (cognitive-behavioral therapy, gut-directed hypnotherapy) for refractory cases. Alarm features require upper endoscopy.
- Main risks
- Bleeding from bite sites for 6 to 24 hours after detachment
- Bruising and tenderness over the upper abdomen
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Trigger of nausea or worsening dyspeptic symptoms
- Risk of missed underlying gastric ulcer, malignancy, or H. pylori infection
- Delay of proton pump inhibitor or H. pylori eradication therapy
- Substitution for low-dose tricyclic antidepressant or psychological therapy in refractory cases
- Who should not consider this
- Patients with alarm features (unintentional weight loss, anemia, dysphagia, persistent vomiting, hematemesis, melena, palpable mass)
- Patients who have not been tested for Helicobacter pylori
- Patients with active peptic ulcer disease or gastric malignancy
- Patients on anticoagulants, with hemophilia, or with anemia
- Pregnant patients
- Patients who have not tried proton pump inhibitor for 4-8 weeks
- What to ask your clinician
- Have I been tested for Helicobacter pylori (urea breath test or stool antigen)?
- Have I had upper endoscopy if I have any alarm features?
- Have I tried a proton pump inhibitor for 4-8 weeks?
- Am I a candidate for low-dose tricyclic antidepressant (amitriptyline 10-25 mg)?
- Have I been offered cognitive-behavioral therapy or gut-directed hypnotherapy?
- What evidence specifically supports leech therapy for functional dyspepsia?
- What is the cost and is it covered by insurance? (typically not covered)
- When to seek urgent care
- Vomiting blood or coffee-ground material (possible upper GI bleeding)
- Passing black tarry stools (possible GI bleeding)
- Unintentional weight loss, anemia, or dysphagia (alarm features — endoscopy needed)
- Severe abdominal pain (possible peptic ulcer perforation)
- Persistent vomiting or inability to keep down food
- Spreading redness, warmth, pus, or red streaks (cellulitis)
- Fever above 38.0 C / 100.4 F or chills
- Hives, facial or tongue swelling, throat tightness, or breathing difficulty
What this does NOT mean
- This is NOT FDA-cleared for functional dyspepsia.
- With no clinical study identified, efficacy versus H. pylori eradication, proton pump inhibitor, or low-dose tricyclic antidepressant is unknown.
- It does NOT replace upper endoscopy when alarm features are present.
- It does NOT substitute for evidence-based pharmacologic and psychological therapy.
- It does NOT distinguish functional dyspepsia from peptic ulcer disease or gastric malignancy.
Safety cross-references
Clinical Profile
- Category
- Gastrointestinal
- ICD-10
- K30
- Safety tier
- Medium
Evidence Summary
Functional dyspepsia (Rome IV) is epigastric pain or postprandial distress syndrome without identifiable structural or biochemical cause, after upper endoscopy and H. pylori testing. Evidence-based stepwise management is H. pylori eradication when positive, proton pump inhibitor trial (4-8 weeks), prokinetics (acotiamide where available, or metoclopramide short-term with cardiac caution), low-dose tricyclic antidepressants for refractory pain-predominant disease, and dietary modification. Hypnotherapy and cognitive behavioral therapy have RCT support. No clinical study or case report of leech therapy for functional dyspepsia was identified in PubMed, Europe PMC, Crossref or ClinicalTrials.gov (searched October 2026). The only Russian clinical reports found concern organic gastric disease, not functional dyspepsia: the 2004 Baskova and Isakhanyan monograph describes 30 patients with gastric ulcer observed by Kamenev (1999) who received leeches together with phytotherapy and aromatherapy (no control group is described), and mentions only isolated cases in chronic gastritis. The primary reports were not retrieved, and these data cannot be read as evidence for functional dyspepsia.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)
Contraindications
- Hemophilia or another bleeding disorder
- Taking anticoagulants (blood thinners such as warfarin or heparin)
- Anemia or suppressed blood formation
- Low blood pressure, shock, collapse or fainting
- Severe wasting (cachexia)
- Intolerance of leeches or a history of severe allergic reactions
- Pregnancy
- Stomach or duodenal ulcer, erosive gastritis
- Acute infectious disease or high fever
- Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
- Drinking alcohol at the time of treatment
- No consent from the patient
- Untreated H. pylori infection (treat first)
- Active peptic ulcer disease or upper GI bleeding
- Suspected gastric malignancy on endoscopy
- Prior gastric surgery or bariatric procedure
Related Conditions
Chronic Pancreatitis (Investigational Pain Adjunct)
Highly investigational adjunct for chronic pancreatitis pain refractory to conventional therapy; no clinical study identified; pancreatic enzyme replacement and pain medicine remain primary.
Non-Alcoholic Fatty Liver Disease (Investigational Adjunct)
Investigational adjunct in NAFLD/MASLD; no human clinical study identified; weight loss, dietary modification, and resmetirom remain primary.
Hepatic Portal Congestion (Non-Cirrhotic, Investigational)
Highly investigational adjunct for non-cirrhotic hepatic congestion; uncontrolled Russian series only; cirrhosis and portal hypertension are absolute exclusions.
Hemorrhoids (Grade II-III, Symptomatic)
Investigational use for symptomatic relief of grade II-III internal/external hemorrhoidal disease; does not address anatomic prolapse.